S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
TSE:CXR

Concordia International Stock Forecast, Price & News

Add
Compare
Today's Range
N/A
50-Day Range
C$25.04
C$25.04
52-Week Range
N/A
Volume
73,541 shs
Average Volume
4,054 shs
Market Capitalization
C$1.22 billion
P/E Ratio
0.07
Dividend Yield
N/A
Beta
N/A

Receive CXR News and Ratings via Email

Sign-up to receive the latest news and ratings for Concordia International and its competitors with MarketBeat's FREE daily newsletter.


Concordia International logo

About Concordia International

Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Tetroxin drug for severe hypothyroid states; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; and Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; and Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria. This segment also offers photodynamic therapy with Photofrin for the treatment of certain forms of cancer that combines a photosensitizing agent with a specific type of laser that emits an exact wavelength of light and power to target cancer cells. The company sells its products through direct sales and local partnerships. The company was formerly known as Concordia Healthcare Corp. and changed its name to Concordia International Corp. in 2016. Concordia International Corp. is headquartered in Oakville, Canada.

Headlines

Morning News Call - Canada, March 15
October 27, 2021 |  finance.yahoo.com
Miami Area Job Openings: See The Latest
February 22, 2021 |  msn.com
UPDATE 2-Nordic Capital offers to buy Advanz Pharma
January 28, 2021 |  cn.reuters.com
Concordia Maritime appoints new CFO
December 11, 2020 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
C$569.62 million
Book Value
C$6.08 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
C$1.22 billion
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.10 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -












Concordia International (TSE:CXR) Frequently Asked Questions

Who are Concordia International's key executives?

Concordia International's management team includes the following people:
  • Mr. Graeme Neville Duncan, CEO & Director (Age 44)
  • Mr. Karl Ian Belk, Chief Operations Officer
  • Mr. Adeel Ahmad, Chief Financial Officer (Age 44)
  • Mr. Adam Peeler, VP of Investor Relations & Communications
  • Mr. Robert Sully, Gen. Counsel

What other stocks do shareholders of Concordia International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Concordia International investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), AbbVie (ABBV), Vermilion Energy (VET), (CXRX) (CXRX), Wheaton Precious Metals (WPM), Rogers Communications (RCI) and Open Text (OTEX).

What is Concordia International's stock symbol?

Concordia International trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CXR."

How do I buy shares of Concordia International?

Shares of CXR and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

How much money does Concordia International make?

Concordia International has a market capitalization of C$0.00 and generates C$569.62 million in revenue each year.

What is Concordia International's official website?

The official website for Concordia International is concordiarx.com.

Where are Concordia International's headquarters?

Concordia International is headquartered at 277 Lakeshore Rd E Suite 302, OAKVILLE, ON L6J 1H9, Canada.

How can I contact Concordia International?

Concordia International's mailing address is 277 Lakeshore Rd E Suite 302, OAKVILLE, ON L6J 1H9, Canada. The company can be reached via phone at +1-905-8425150.


This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.